Predicting drug responsiveness in cancer patients

Jul 26, 2010

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

Specifically, the team found that human cells with in the PIK3CA gene responded to everolimus in vitro except when a KRAS gene mutation was also present. Importantly, in a cohort of metastatic cancer patients, the presence of KRAS gene mutations was associated with lack of response to treatment with everolimus therapy.

These data suggest that by looking for the presence or absence of PIK3CA and KRAS mutations in a person's tumor it will be possible to predict whether or not that person will benefit from treatment with a drug that targets mTOR. However, as noted in an accompanying commentary, by Morassa Mohseni and Ben Ho Park, at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, while these data have enormous potential to change clinical practice, larger prospective studies are required to verify them.

Explore further: New research leads to FDA approval of first drug to treat radiation sickness

More information: www.jci.org/articles/view/37539?key=fd893349707da2f3dddf

Related Stories

Colon cancer may yield to cellular sugar starvation

Aug 06, 2009

Scientists at the Johns Hopkins Kimmel Cancer Center have discovered how two cancer-promoting genes enhance a tumor's capacity to grow and survive under conditions where normal cells die. The knowledge, they say, may offer ...

Recommended for you

Vortex device makes for better cancer treatments

22 hours ago

A South Australian invention, responsible for unboiling an egg, has been used to produce a four-fold increase in efficacy of carboplatin, a commonly used drug for ovarian, lung and other cancer. ...

Using healthy skin to identify cancer's origins

May 21, 2015

Normal skin contains an unexpectedly high number of cancer-associated mutations, according to a study published in Science. The findings illuminate the first steps cells take towards becoming a cancer and de ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.